Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Court Hands Novartis Setback In Gleevec Patent Case

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis says decision will have innovation, intellectual property repercussions for other pharma firms operating in India.

You may also be interested in...



Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings

Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations

Roche's Passage To India: Repetitive Patent Hearings, Uncertain Rulings

Patent litigation is always uncertain, but in India pharma companies confront unusual hurdles: separate proceedings when a patent is challenged by numerous opponents; conflicting rulings; a 10-year review backlog; and a law limiting the patenting of new formulations

Novartis Pitching New Product: A Fund For Tropical Disease Research

Novartis executive Paul Herrling has been on a whirlwind promotional tour the past few weeks. He's met with government leaders in China, Germany and the Netherlands, and academicians at Yale University, Columbia University and the New York Academy of Sciences. His goal: convincing them to support a new way to fund research on medicines for tuberculosis, dengue fever and other neglected tropical diseases

Related Content

Topics

UsernamePublicRestriction

Register

PS066548

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel